Group 1 - The accounting policy change is in accordance with the latest accounting standards revised by the Ministry of Finance and will not have a significant impact on the company's financial status, operating results, or cash flow [1][2] - The board of directors believes that the accounting policy change is reasonable and does not harm the interests of the company and all shareholders [1][2] - The supervisory board also agrees that the accounting policy change is a reasonable adjustment that complies with relevant laws and regulations [2] Group 2 - The company announced the cancellation of part of the granted but unvested restricted stock from the 2022 incentive plan due to performance assessment not meeting the targets [10][12] - A total of 336,376 shares of restricted stock will be canceled, including 316,518 shares due to unmet performance targets and 18,188 shares due to the departure of nine incentive recipients [10][12] - The cancellation of these shares will not harm the interests of the company and all shareholders and will not significantly impact the company's financial status or operating performance [10][12] Group 3 - The company will hold the 2024 annual general meeting on May 13, 2025, at 14:30, with both on-site and online voting options available for shareholders [16][19] - The meeting will include voting on various proposals, with special resolutions requiring approval from at least two-thirds of the voting rights present [22][24] - Shareholders must register for the meeting in advance, with specific procedures outlined for both corporate and individual shareholders [25][26]
上海优宁维生物科技股份有限公司